Pharmaceuticals, Volume 10, Issue 1 (March 2017) – 32 articles
Cover Story (view full-size image): Radiotheranostics combining diagnostic imaging and radiotherapeutic treatment fulfil the criteria of personalized medicine on molecular level. In particular, peptide receptor targeting mechanism has demonstrated strong potential in the clinical management of neuroendocrine neoplasms (NENs) wherein radiolabeled somatostatin analogs targeting somatostatin receptors (SSTR) has entered clinical practice. Other receptors expressed in various NENs such as Glucagon-Like Peptide-1 Receptor and Cholecystokinin-2 receptor approached clinical research, and Glucose-Dependent Insulinotropic Polypeptide (GIP) receptor has the potential for SSTR-negative and GLP-1R-negative NENs. The current status of radiotheranostics in NENs proves that peptide-receptor targeting nuclear imaging and therapy is an indispensable clinical tool in oncology. View this paper
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.